Dynavax Technologies Corporation (NASDAQ:DVAX) Finds Place On Cowen List


Dallas, Texas 01/24/2014 (FINANCIALSTRENDS) – Dynavax Technologies Corporation (NASDAQ:DVAX) has also been included in analyst Cowen’s top bio technology stocks that investors should buy in 2014. Though the company has declared higher upside for companies such as Amgen, Biogen, Nektar Therapeutics, it does include CMRX and DVAX on its list.

Dynavax Technologies Corporation (NASDAQ:DVAX) main product candidate is HEPLISAV. This candidate is currently being tested as a vaccine to overcome Hepatitis B in adults. It is in Phase 3 investigational stage for the same. The product will be administered along with other vaccines, but in lower dosages. The company will also expect to provide higher protection as well as quicker protection. Dynavax is known to work with other third parties to develop other therapies. Its autoimmune program is being run by GlaxoSmithKline (GSK), while its asthma therapy will be run by AstraZeneca AB. The former will work closely with Dynavax on other therapies such as Universal Flu vaccine as well as Hepatitis B therapy.

Dynavax Technologies Corporation (NASDAQ:DVAX) a Berkeley based bio technology major has  since  been working on safety data that was requested by the Food and Drug Administration post the phase 3 trails for Heplisav.

Dynavax Technologies Corporation (NASDAQ:DVAX) is expected to move higher on its sequencing method, as the company has since developed it and is currently a proprietary process. The company also holds interest in two subsidiaries operating in Netherlands-Rhein Biotech GmbH as well as Dynavax International B.V.

Dynavax Technologies Corporation (NASDAQ:DVAX) at end of trading yesterday closed at $1.94. This was slide downwards of 1.02%.  Volume trades were at 5.84 million shares, much higher than average trading volume of 5.09 million shares. Tody, the company value is at $509.49 million. Dynavax Technologies Corporation (Dynavax) operates as a clinical-stage biopharmaceutical company, providing products which it both develops and produces for the prevention of infectious diseases as well as inflammatory diseases.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.